 |
|
New guideline for prescribing opioid pain drugs published
February 09, 2009Researchers at Oregon Health & Science University provide evidence to support first published guideline for treating chronic non-cancer pain with opioid medications
A national panel of pain management experts representing the American Pain Society (APS) and the American Academy of Pain Medicine (AAPM) has published the first comprehensive, evidence-based clinical practice guideline to assist clinicians in prescribing potent opioid pain medications for patients with chronic non-cancer pain. The long-awaited guideline appears in the current issue of The Journal of Pain, www.jpain.org.
To create this guideline, researchers in the Oregon Evidence-based Practice Center (EPC) at Oregon Health & Science University collaborated with the APS and AAPM for two years, reviewing more than 8,000 published abstracts and nonpublished studies to assess clinical evidence on which the new recommendations are based.
"This guideline was a true multidisciplinary effort that sought to address in a balanced manner the many challenging issues that clinicians face with regard to when and how to prescribe opioids for chronic noncancer pain," said Roger Chou, M.D., principal investigator; director of the American Pain Society Clinical Practice Guidelines Program; scientific director of the Oregon Evidence-Based Practice Center at OHSU; and associate professor of medical informatics and clinical epidemiology, and medicine (general internal medicine and geriatrics) in the OHSU School of Medicine.
"A key part of this process was performing a comprehensive literature review to inform the recommendations - though an important take-home message is that even though the recommendations represent the best judgment of the panel based on the currently available literature, there is still a lot of research that needs to be done."
The expert panel concluded that opioid pain medications are safe and effective for carefully selected, well-monitored patients with chronic non-cancer pain. They made 25 specific recommendations and achieved unanimous consensus on nearly all.
Opioid prescribing has increased significantly due to growing professional acceptance that the drugs can relieve chronic non-cancer pain, and the guideline acknowledges there are widespread concerns about increases in prescription opioid abuse, addiction and diversion.
Opioids, such as morphine, oxycodone, oxymorphone and fentanyl are potent analgesics. They traditionally have been used to relieve pain following surgery, from cancer and at the end of life. Today opioids are used widely to relieve severe pain caused by chronic low-back injury, accident trauma, crippling arthritis, sickle cell, fibromyalgia, and other painful conditions.
Prior to initiating chronic opioid therapy, the guideline advises clinicians to determine if the pain can be treated with other medications. If opioids are appropriate, the clinician should conduct a thorough medical history and examination and assess potential risk for substance abuse, misuse or addiction.
Diligent Patient Monitoring Is Essential
A key recommendation urges clinicians to continuously assess patients on chronic opioid therapy by monitoring pain intensity, level of functioning and adherence to prescribed treatments. Periodic drug screens should be ordered for patients at risk for aberrant drug behavior.
Other recommendations in the APS/AAPM clinical practice guideline include:
* Methadone: Use of methadone for pain management has increased dramatically but few trials have evaluated its benefits and harms for treatment of chronic non-cancer pain. Methadone, therefore, should be started at low doses and titrated slowly. Because of its long half-life and variable pharmacokinetics, the panel recommends methadone not be used to treat breakthrough pain or as an as-needed medication.
* Abusers: Chronic opioid therapy must be discontinued in patients known to be diverting their medication or in those engaging in serious aberrant behaviors.
* Breakthrough Pain: As-needed opioids can be prescribed based on initial and ongoing analysis of therapeutic benefit versus risk.
* High Doses: Patients who need high doses of opioids (200 mg daily of morphine or equivalent) should be evaluated for adverse events on an ongoing basis, and clinicians should consider rotating pain medications when patients experience intolerable side effects or inadequate benefit despite appropriate dose increases.
* Driving and Work Safety: Patients should be educated about the greater risk for impairment when starting chronic opioid therapy and counseled not to drive or engage in potentially dangerous work if impaired.
* Pregnancy: Clinicians should counsel women about risks of opioids in pregnancy and encourage minimal or no use of chronic opioid therapy unless potential benefits outweigh risks.
The guideline on opioid therapy for chronic non-cancer pain is the first such collaboration between APS and AAPM. It is the sixth evidenced-based, pain management clinical practice guideline published by APS. Others have covered sickle-cell disease, arthritis, cancer, fibromyalgia, and low back pain.
Oregon Health & Science University
"This guideline was a true multidisciplinary effort that sought to address in a balanced manner the many challenging issues that clinicians face with regard to when and how to prescribe opioids for chronic noncancer pain," said Roger Chou, M.D., principal investigator; director of the American Pain Society Clinical Practice Guidelines Program; scientific director of the Oregon Evidence-Based Practice Center at OHSU; and associate professor of medical informatics and clinical epidemiology, and medicine (general internal medicine and geriatrics) in the OHSU School of Medicine.
"A key part of this process was performing a comprehensive literature review to inform the recommendations - though an important take-home message is that even though the recommendations represent the best judgment of the panel based on the currently available literature, there is still a lot of research that needs to be done."
The expert panel concluded that opioid pain medications are safe and effective for carefully selected, well-monitored patients with chronic non-cancer pain. They made 25 specific recommendations and achieved unanimous consensus on nearly all.
Opioid prescribing has increased significantly due to growing professional acceptance that the drugs can relieve chronic non-cancer pain, and the guideline acknowledges there are widespread concerns about increases in prescription opioid abuse, addiction and diversion.
Opioids, such as morphine, oxycodone, oxymorphone and fentanyl are potent analgesics. They traditionally have been used to relieve pain following surgery, from cancer and at the end of life. Today opioids are used widely to relieve severe pain caused by chronic low-back injury, accident trauma, crippling arthritis, sickle cell, fibromyalgia, and other painful conditions.
Prior to initiating chronic opioid therapy, the guideline advises clinicians to determine if the pain can be treated with other medications. If opioids are appropriate, the clinician should conduct a thorough medical history and examination and assess potential risk for substance abuse, misuse or addiction.
Diligent Patient Monitoring Is Essential
A key recommendation urges clinicians to continuously assess patients on chronic opioid therapy by monitoring pain intensity, level of functioning and adherence to prescribed treatments. Periodic drug screens should be ordered for patients at risk for aberrant drug behavior.
Other recommendations in the APS/AAPM clinical practice guideline include:
* Methadone: Use of methadone for pain management has increased dramatically but few trials have evaluated its benefits and harms for treatment of chronic non-cancer pain. Methadone, therefore, should be started at low doses and titrated slowly. Because of its long half-life and variable pharmacokinetics, the panel recommends methadone not be used to treat breakthrough pain or as an as-needed medication.
* Abusers: Chronic opioid therapy must be discontinued in patients known to be diverting their medication or in those engaging in serious aberrant behaviors.
* Breakthrough Pain: As-needed opioids can be prescribed based on initial and ongoing analysis of therapeutic benefit versus risk.
* High Doses: Patients who need high doses of opioids (200 mg daily of morphine or equivalent) should be evaluated for adverse events on an ongoing basis, and clinicians should consider rotating pain medications when patients experience intolerable side effects or inadequate benefit despite appropriate dose increases.
* Driving and Work Safety: Patients should be educated about the greater risk for impairment when starting chronic opioid therapy and counseled not to drive or engage in potentially dangerous work if impaired.
* Pregnancy: Clinicians should counsel women about risks of opioids in pregnancy and encourage minimal or no use of chronic opioid therapy unless potential benefits outweigh risks.
The guideline on opioid therapy for chronic non-cancer pain is the first such collaboration between APS and AAPM. It is the sixth evidenced-based, pain management clinical practice guideline published by APS. Others have covered sickle-cell disease, arthritis, cancer, fibromyalgia, and low back pain.
Oregon Health & Science University
Opioids Current Events and Opioids News RSSInfant pain, adult repercussions
Scientists at Georgia State University have uncovered the mechanisms of how pain in infancy alters how the brain processes pain in adulthood.
First results from major European patient survey show devastating impact of living with breakthrough cancer pain
The first results of the first European survey of cancer patients' experience of breakthrough pain were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).
Rats Move Toward the Food but Do Not Eat
Scientists led a rat to the fatty food, but they couldn't make it eat. Using an animal model of binge eating, University of Missouri researchers discovered that deactivating the basolateral amygdala, a brain region involved in regulating emotion, specifically blocked consumption of a fatty diet. Surprisingly, it had no effect on the rat wanting to look for the food repeatedly.
Researchers find genetic link between physical pain and social rejection
UCLA psychologists have determined for the first time that a gene linked with physical pain sensitivity is associated with social pain sensitivity as well.
A comprehensive review of addiction to prescription painkillers among patients and physicians
Chemical dependency and recovery in patients and physicians are closely examined in a series of articles and editorials in the July 2009 issue of Mayo Clinic Proceedings.
Effective pain treatment for cancer patients?
Cancer patients often suffer from severe pain that cannot be effectively treated with conventional medication.
Regulation of cell proliferation by the OGF-OGFr axis is dependent on nuclear localization signals
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the efficacy of the Opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically important antitumor agent, is dependent on nucleocytoplasmic translocation and reliant on the integrity of nuclear localization signals in the OGF receptor (OGFr).
New guidelines for prescribing opioid pain drugs published
A prestigious panel of pain-management experts representing the American Pain Society (APS) www.ampainsoc.org and the American Academy of Pain Medicine (AAPM) has published the first comprehensive clinical practice guideline to assist clinicians in prescribing potent opioid pain medications for patients with chronic non-cancer pain.
Extended-treatment with combination medication for opioid-addicted youths shows benefit
Adolescents addicted to opioids who received continuing treatment with the combination medication buprenorphine-naloxone had lower rates of testing positive or reporting use of opioids compared to youths who went through a short-term detoxification program using the same medication, according to a study in the November 5 issue of JAMA.
Study examines use of opioids
Researchers from Boston University's Slone Epidemiology Center have found that in a given week, over 10 million Americans are taking opioids, and more than 4 million are taking them regularly (at least five days per week, for at least four weeks). These findings appear in the August 31 issue of the journal Pain.
More Opioids Current Events and Opioids News Articles
 |
Demystifying Opioid Conversion Calculations: A Guide to Effective Dosing by Mary Lynn McPherson (Author) Against a backdrop of the growing scrutiny of appropriate dosages, this textbook takes a fresh, new approach to helping health professionals strengthen care to and possibly save the lives of patients living with pain. This easy-to-understand and often humorous book is the most comprehensive to-date on opioid calculations for pain management and palliative care. It carefully walks clinicians through a five-step process for performing opioid conversion calculations in the real-world situations they often see. The book has case examples, simple charts and tables, and practice problems throughout. It is a must for clinicians at all levels: hospice and palliative care physicians, physician s assistants, nurses, nurse practitioners, and pharmacists. Clinicians will come away with more... |
 |
Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners by Lynn R. Webster M.D. and Beth Dove (Author) Prescription opioids are dangergous in the hands of drug abusers, but they are also beneficial or even lifesaving for millions of people who otherwise would live with chronic pain. Clinicians who prescribe opioids are often caught between their professional obligation to relieve suffering and their desire to avoid contributing to the non-medical consumption of controlled substances. Primary care physicians, nurse practioners and other first-contact clinicians are uniquely positioned to make a difference at the beginning of medical treatment. Research indicates that a patient with chronic pain or a substance-abuse disorder is far more likely to seek treatment from a family doctor than from a specialist. That reality creates an opportunity for front-line clinicians to maximize the... |
 |
Opioid The Peace Leeches (Primary Contributor) |
|
Axxora Naloxone Hydrochloride, 50 MG by Axxora The product referenced on this detail page is sold be Each. | |
 |
Responsible Opioid Prescribing A physician's Guide by MD Scott M. Fishman (Author) |
 |
Paranoid Opioid Corrosion Of Conformity (Primary Contributor) |
 |
Opioid-Induced Hyperalgesia by Jianren Mao (Editor) Highlights in Opioid-Induced Hyperalgesia: GROUNDBREAKING CONTENT - the first clinically focused text dedicated to the newly emerging area of pain medicine known as opioid-induced hyperalgesia (OIH) provides pain specialists, anesthesiologists, and neurologists with the most current, cutting-edge research and therapeutic options for treating OIH patients EXPER CONTRIBUTORSHIP - 12 experienced key opinion leaders in the field supply best practice guidelines for the effective assessment, diagnosis, and management of OIH: need-to-know information clinicians trust and can utilize in their practices CLEAR ORGANIZATION - of chapters by type of high-risk patient- the cancer patient, the post-op patient, and the chronic and acute pain patient-enables clinicians to quickly and... |
 |
Basic and Clinical Science of Opioid Addiction (Bibliotheca Psychiatrica) by Marcus F. Kuntze (Editor), Franz Muller-Spahn (Editor), Dieter Ladewig (Editor), Alex H. Bullinger (Editor) For the first time, reports on methadone and heroin maintenance treatment with respect to clinical practice, research, methodological aspects, neuroscience and psychotherapy are brought together in this volume. They arise from a conference held in November 2001 in Basel. The Swiss approach of a highly structured outpatient treatment using methadone, heroin, morphine etc. to keep patients in treatment is discussed. Data of follow-up after heroin-assisted treatment is shown. Also a critical discussion of the history of treatment modalities and its scientific evaluation is presented. Further important topics such as brain imaging, opioid withdrawal, risks of treatment, and basic neurochemical research are presented. The issue concludes with the narrative experience of a practicing... |
 |
Handbook of Opioid Bowel Syndrome by Chun-Su, Ph.D. Yuan (Editor) How can medical professionals take advantage of the valuable effects of opiates while minimizing their most common side effect—opioid bowel syndrome? This groundbreaking book will help physicians in their day-to-day practice and help researchers and educators prepare the next generation of clinicians to make more efficient use of opioids. The Handbook of Opioid Bowel Syndrome presents complete, authoritative, current information on the mechanisms of action of opioids and the management of opioid bowel dysfunction-the number one reason physicians avoid prescribing opioids. Most chapters include charts, tables, and/or illustrations that make complex information about this vexing problem easy to access and understand. All are well-referenced for further study. From... |
 |
The Treatment of Opioid Dependence by Eric C. Strain MD (Editor), Maxine L. Stitzer PhD (Editor) The successor to Strain and Stitzer's Methadone Treatment for Opioid Dependence (Johns Hopkins, 1999), this expanded and updated volume reflects new developments in treatment protocols. Methadone is still the most widely used medication for the treatment of opioid dependence, and the authors provide an extensive section on methadone treatment. Three chapters cover the pharmacology and clinical use of buprenorphine as well as the latest research on Naltrexone, Clonidine, and Lofexidine. The volume also includes chapters on pain and prescription opioids as well as medication-free treatment and medically supervised alternatives to opioid substitute treatments, including withdrawal. The Treatment of Opioid Dependence will be a valuable resource for methadone counselors,... |
| © 2009 BrightSurf.com |